COYA Coya Therapeutics, Inc.
USHealthcareAs of 2026-07-09 11:02
Why COYA matters now
Coya Therapeutics, Inc. (COYA) is a US stock in Healthcare. The latest InvestLog snapshot shows $5.44 with +1.49% on the session and $99.1M in market capitalization; recent performance reads 1-month +7.66% and YTD -15.17%.
The latest financial table shown here is Q1 2026, with revenue of $251.1K, net income of $-7.2M, and EPS of $-0.32. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -15.8%.
The latest indexable market news headline is "Is Coya Therapeutics, Inc. (COYA) Stock Outpacing Its Medical Peers This Year?" from Zacks Investment Research.
Additional event context on this page matters because analyst consensus is Buy with a median target of $12.00; recent insider activity includes Pavao Mark H filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
1.68
P/S
11.28
EV/EBITDA
-1.84
DCF Value
$4.83
FCF Yield
-15.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
99.8%
Operating Margin
-277.0%
Net Margin
-266.1%
ROE
-57.3%
ROA
-39.7%
ROIC
-44.2%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $251.1K | $-7.2M | $-0.32 |
| Q4 2025 | $4.0M | $-5.7M | $-0.34 |
| FY 2025 | $7.9M | $-21.2M | $-1.27 |
| Q3 2025 | $3.6M | $-2.1M | $-0.13 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$12.00
Target (Median)
$12.00
Target Range
$12.00 - $12.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.62
Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative therapeutic agents that fine-tune the function of regulatory T cells (Tregs). Its therapeutic pipeline leverages diverse approaches, including biologics designed to enhance Treg activity, Treg-derived exosomes, and personalized autologous Treg cell therapies. Among its lead candidates is COYA 101, an autologous regulatory T-cell product that has successfully completed Phase 2a clinical trials for treating Amyotrophic Lateral Sclerosis (ALS). Moving towards Investigational New Drug (IND) applications are two key candidates: COYA 301 and COYA 302. COYA 301 is a Treg-enhancing biologic aimed at treating Frontotemporal Dementia. Meanwhile, COYA 302 is a dual-action biologic combination, suitable for subcutaneous or intravenous delivery, engineered to not only boost Treg function but also to diminish harmful T effector cell activity and activated macrophages in neurodegenerative and autoimmune disorders. Additionally, Coya has earlier-stage programs, including COYA 201, an allogeneic (off-the-shelf) Treg exosome candidate in preclinical development for a range of neurodegenerative, autoimmune, and metabolic conditions. Its pipeline also features COYA 206, an antigen-directed Treg-derived exosome product, currently in the discovery phase. Established in 2020, Coya Therapeutics maintains its headquarters in Houston, Texas.